Oberhauser V, Vonend O, Rump L C
Medizinische Universitätsklinik Freiburg, Innere Medizin IV, Germany.
J Am Soc Nephrol. 1999 Jun;10(6):1179-85. doi: 10.1681/ASN.V1061179.
Neuropeptide Y (NPY) and ATP are cotransmitters of norepinephrine (NE). Modulation of ATP-mediated purinergic neurotransmission by NPY was investigated in rat perfused kidney. Beta,gamma-Methylene-L-ATP (beta,gamma-mATP; 1.0 to 1.5 microM, n = 8), NE (0.1 microM, n = 8), and NPY (0.1 microM, n = 14) increased perfusion pressure by maximally 12 +/- 1, 17 +/- 2, and 9 +/- 1 mmHg, respectively. In the presence of NPY, responses to ATP and NE were dramatically enhanced. Renal nerve stimulation in the presence of the alpha-adrenoceptor antagonist phentolamine (1 microM) induced pressor responses of 54 +/- 5 mmHg (n = 6). Alpha-blockade-resistant responses were abolished by the P2-purinoceptor blocker suramin (300 microM) and thus mediated by ATP. Purinergic responses were also reduced significantly (50%) by the NPY-Y1 receptor blocker BIBP 3226 (1 microM). NPY (0.1 microM) potentiated purinergic pressor responses and enhanced ATP release from 0.7 +/- 0.2 to 4.1 +/- 0.9 pmol (n = 4) associated with a significant increase of soluble ATPase activity. All NPY effects were prevented by BIBP 3226. Pressor responses to renal nerve stimulation delivered at short time intervals, mimicking enhanced sympathetic drive to the kidney, were not constant but showed a progressive rise, which was prevented by BIBP 3226. In this study, it is suggested that purinergic vasoconstriction in rat kidney depends on concomitantly released NPY. NPY by itself is only a weak vasoconstrictor but acts as a modulator of renal vascular resistance by enhancing the effects of its sympathetic cotransmitters, especially during sympathetic overactivity.
神经肽Y(NPY)和ATP是去甲肾上腺素(NE)的共递质。在大鼠灌注肾中研究了NPY对ATP介导的嘌呤能神经传递的调节作用。β,γ-亚甲基-L-ATP(β,γ-mATP;1.0至1.5微摩尔,n = 8)、NE(0.1微摩尔,n = 8)和NPY(0.1微摩尔,n = 14)分别使灌注压最大升高12±1、17±2和9±1毫米汞柱。在存在NPY的情况下,对ATP和NE的反应显著增强。在α-肾上腺素能受体拮抗剂酚妥拉明(1微摩尔)存在下刺激肾神经,可诱导54±5毫米汞柱的升压反应(n = 6)。P2嘌呤能受体阻滞剂苏拉明(300微摩尔)可消除α-受体阻断抗性反应,因此该反应由ATP介导。NPY-Y1受体阻滞剂BIBP 3226(1微摩尔)也可使嘌呤能反应显著降低(50%)。NPY(0.1微摩尔)增强了嘌呤能升压反应,并使ATP释放量从0.7±0.2皮摩尔增加至4.1±0.9皮摩尔(n = 4),同时可溶性ATP酶活性显著增加。所有NPY的作用均被BIBP 3226阻断。短时间间隔刺激肾神经引起的升压反应,模拟了增强的肾脏交感神经驱动,并非恒定不变,而是呈逐渐上升趋势,这一现象被BIBP 3226阻断。在本研究中,提示大鼠肾脏中的嘌呤能血管收缩取决于同时释放的NPY。NPY本身只是一种弱血管收缩剂,但通过增强其交感共递质的作用,尤其是在交感神经活动亢进期间,作为肾血管阻力的调节剂发挥作用。